<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390399</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-88</org_study_id>
    <nct_id>NCT04390399</nct_id>
  </id_info>
  <brief_title>Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate&#xD;
      the comparative efficacy and overall safety of standard-of-care chemotherapy versus&#xD;
      standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK&#xD;
      in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting&#xD;
      (ie, first line maintenance, second line, or third line or greater) will be evaluated&#xD;
      independently as a separate cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Response Criteria in Solid Tumors (RECIST) V1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR), Complete response (CR) rate, and Disease Control Rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Response Criteria in Solid Tumors (RECIST) V1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>2 years</time_frame>
    <description>Patient Reported Outcomes (PROs) using the Functional Assessment of Cancer Therapy - Hepatobiliary Cancer (FACT-Hep) Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A Control Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SBRT + gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Control Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan liposome + 5-FU/leucovorin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>N-803</intervention_name>
    <description>Recombinant human super agonist interleukin-15 (IL-15) complex</description>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldoxorubicin HCl</intervention_name>
    <description>Aldoxorubicin hydrochloride</description>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-L1 t-haNK</intervention_name>
    <description>PD-L1 t-haNK suspension for infusion</description>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin</description>
    <arm_group_label>Cohort A Control Treatment Arm</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>2', 2'-difluoro 2'deoxycytidine, dFdC</description>
    <arm_group_label>Cohort A Control Treatment Arm</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate</description>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-fluoro-2,4 (1H,3H)-pyrimidinedione</description>
    <arm_group_label>Cohort B Control Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt</description>
    <arm_group_label>Cohort B Control Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic Body Radiation Therapy</description>
    <arm_group_label>Cohort A Control Treatment Arm</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 1</arm_group_label>
    <arm_group_label>Cohort A Experimental Treatment Arm 2</arm_group_label>
    <arm_group_label>Cohort B Experimental Treatment Arm</arm_group_label>
    <arm_group_label>Cohort C Experimental Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan liposome</intervention_name>
    <description>Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate</description>
    <arm_group_label>Cohort B Control Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or IEC guidelines.&#xD;
&#xD;
          3. Have histologically confirmed unresectable, locally advanced or metastatic pancreatic&#xD;
             cancer.&#xD;
&#xD;
               1. For Cohort A, subjects must have initially received, or are currently receiving,&#xD;
                  continuous treatment with gemcitabine plus nab-paclitaxel for at least 16 weeks&#xD;
                  and have confirmed PR, CR, or SD prior to receiving first-line maintenance&#xD;
                  therapy on this study. Duration of actual initial treatment may be unlimited as&#xD;
                  long as no evidence of disease progression is noted by the Investigator at the&#xD;
                  time of randomization.&#xD;
&#xD;
               2. For Cohort B, subjects must have PD after receiving initial treatment with&#xD;
                  FOLFOX, FOLFIRINOX, or a gemcitabine- or paclitaxel-based therapy for pancreatic&#xD;
                  cancer.&#xD;
&#xD;
                  Subjects who discontinued prior therapy due to toxicity, intolerance, or&#xD;
                  available therapy was clinically contraindicated are allowed.&#xD;
&#xD;
               3. For Cohort C, subjects must have PD after receiving at least 2 lines of therapy&#xD;
                  for pancreatic cancer, including but not limited to neoadjuvant, adjuvant, and/or&#xD;
                  metastatic settings.&#xD;
&#xD;
          4. ECOG PS of 0 or 1.&#xD;
&#xD;
          5. Have at least 1 measurable lesion and/or non-measurable disease evaluable in&#xD;
             accordance with RECIST V1.1.&#xD;
&#xD;
          6. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
          7. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception while on study and for at least 5 months after the last&#xD;
             dose of study treatment. Non-sterile male subjects must agree to use a condom while on&#xD;
             study and for up to 5 months after the last dose of study treatment. Effective&#xD;
             contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two&#xD;
             forms of barrier methods (eg, condom, diaphragm) used with spermicide, IUDs, oral&#xD;
             contraceptives, and abstinence.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Body weight ≤ 40 kg at screening.&#xD;
&#xD;
          2. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, autoimmune disease associated with lymphoma).&#xD;
&#xD;
          4. For Cohort A only: tumors harboring germline BRCA1/2 mutations.&#xD;
&#xD;
          5. For Cohort B only: previous treatment with liposomal irinotecan for advanced or&#xD;
             metastatic pancreatic cancer.&#xD;
&#xD;
          6. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          7. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          8. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1000 cells/mm3.&#xD;
&#xD;
               2. Platelet count &lt; 100,000 cells/mm3.&#xD;
&#xD;
               3. Hemoglobin &lt; 9 g/dL.&#xD;
&#xD;
               4. Total bilirubin greater than two times the upper limit of normal (ULN; unless the&#xD;
                  subject has documented Gilbert's syndrome).&#xD;
&#xD;
               5. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
                  &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases).&#xD;
&#xD;
               6. Alkaline phosphatase (ALP) levels &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver&#xD;
                  metastases, or &gt;10 × ULN in subjects with bone metastases).&#xD;
&#xD;
               7. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               8. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
               9. Albumin &lt;3.0.&#xD;
&#xD;
              10. Ascites requiring paracentesis.&#xD;
&#xD;
             Each site should use its own institution's ULN to determine eligibility.&#xD;
&#xD;
          9. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
         10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
         11. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         12. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         15. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 14 days prior to dosing for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer or FDA-authorized drugs for&#xD;
             the prevention and treatment of COVID-19.&#xD;
&#xD;
         16. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         17. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         18. Pregnant and nursing women. A negative serum pregnancy test during screening and a&#xD;
             negative pregnancy test within 72 hours prior to the first dose must be documented&#xD;
             before study drug is administered to a female subject of child-bearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Fleets, MS</last_name>
    <phone>310-912-4839</phone>
    <email>Jennifer.Fleets@ImmunityBio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Bradshaw</last_name>
      <phone>213-266-5600</phone>
      <email>paula.bradshaw@cssifm.org</email>
    </contact>
    <investigator>
      <last_name>Chaitali Nangia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag memorial Presbyterian Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Blancas</last_name>
      <phone>949-764-5543</phone>
      <email>Rosie.Blancas1@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Tara Seery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Ageton</last_name>
      <phone>888-422-1410</phone>
      <email>navigation@avera.org</email>
    </contact>
    <investigator>
      <last_name>Heidi McKean McKean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

